We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
16 hedge funds and large institutions have $684K invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
48% less funds holding
Funds holding: 31 → 16 (-15)
52% less capital invested
Capital invested by funds: $1.43M → $684K (-$743K)
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Holders
16
Holders Change
-15
Holders Change %
-48.39%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
4
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$129K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.07K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$476 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$396 |
